Indications for alloSCT
| Indication . | All transplanted patients (n = 79) . | CGD (n = 20) . | CID (n = 59) . |
|---|---|---|---|
| Preemptive | 1 (1%) | 0 | 1 (2%) |
| Infection | 10 (13%) | 3 (15%) | 7 (12%) |
| Invasive aspergillosis | 9 (12%) | 9 (45%) | 0 |
| Malignancy∗ | 23 (29%) | 0 | 23 (40%) |
| Autoimmune neutropenia | 8 (10%) | 0 | 8 (14%) |
| Autoimmune hemolytic anemia | 1 (1%) | 0 | 1 (2%) |
| Colitis† | 15 (19%) | 8 (40%) | 7 (12%) |
| Liver involvement‡ | 7 (9%) | 0 | 7 (12%) |
| Hemophagocytic syndrome | 2 (3%) | 0 | 2 (3%) |
| Vasculitis | 2 (3%) | 0 | 2 (3%) |
| Not available | 1 | 0 | 1 |
| Indication . | All transplanted patients (n = 79) . | CGD (n = 20) . | CID (n = 59) . |
|---|---|---|---|
| Preemptive | 1 (1%) | 0 | 1 (2%) |
| Infection | 10 (13%) | 3 (15%) | 7 (12%) |
| Invasive aspergillosis | 9 (12%) | 9 (45%) | 0 |
| Malignancy∗ | 23 (29%) | 0 | 23 (40%) |
| Autoimmune neutropenia | 8 (10%) | 0 | 8 (14%) |
| Autoimmune hemolytic anemia | 1 (1%) | 0 | 1 (2%) |
| Colitis† | 15 (19%) | 8 (40%) | 7 (12%) |
| Liver involvement‡ | 7 (9%) | 0 | 7 (12%) |
| Hemophagocytic syndrome | 2 (3%) | 0 | 2 (3%) |
| Vasculitis | 2 (3%) | 0 | 2 (3%) |
| Not available | 1 | 0 | 1 |
Malignant lymphoproliferative disease (except one patient with Bowen disease).
Crohn-like colitis (except one patient with Cryptosporidium associated-enteropathy).
Nodular regenerative hyperplasia, sclerosing cholangitis, hepatitis T-cell infiltration in 1 patient, and EBV-associated hepatitis in 1 patient.